CESSATECH A/S DK -20 Total Liabilities
CESSATECH A/S DK -20 total liabilities. Based on the latest financial reports, CESSATECH A/S DK -20 (8GN) has total liabilities worth €1.38 Million EUR (≈ $1.61 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 8GN working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of CESSATECH A/S DK -20 (2021–2025)
Total liabilities of CESSATECH A/S DK -20 from 2021 to 2025. This chart illustrates how CESSATECH A/S DK -20's total liabilities have evolved over time, based on quarterly financial data.
CESSATECH A/S DK -20 Competitors by Total Liabilities
The table below lists competitors of CESSATECH A/S DK -20 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Leviathan Gold Ltd
V:LVX
|
Canada | CA$835.69K |
|
VenHub Global, Inc.
NASDAQ:VHUB
|
USA | $8.17 Million |
|
Pivotree Inc
V:PVT
|
Canada | CA$3.71 Million |
|
Innature Bhd
KLSE:5295
|
Malaysia | RM80.33 Million |
|
NV Gold Corp
V:NVX
|
Canada | CA$111.91K |
|
DAP Corporation
KQ:066900
|
Korea | ₩135.71 Billion |
|
Maheshwari Logistics Limited
NSE:MAHESHWARI
|
India | Rs-2.18 Billion |
|
Luster Industries Bhd
KLSE:5068
|
Malaysia | RM298.79 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down CESSATECH A/S DK -20's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CESSATECH A/S DK -20 assets under control.
Liquidity & Leverage Metrics
CESSATECH A/S DK -20 Total Liabilities Ratios Explained
CESSATECH A/S DK -20 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CESSATECH A/S DK -20's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CESSATECH A/S DK -20 (2021–2025)
The table below shows the annual total liabilities of CESSATECH A/S DK -20 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.23 Million ≈ $1.44 Million |
-83.83% |
| 2024-12-31 | €7.63 Million ≈ $8.92 Million |
-26.83% |
| 2023-12-31 | €10.42 Million ≈ $12.19 Million |
+140.60% |
| 2022-12-31 | €4.33 Million ≈ $5.06 Million |
-1.79% |
| 2021-12-31 | €4.41 Million ≈ $5.16 Million |
-- |
About CESSATECH A/S DK -20
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-c… Read more